EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Interim PET‐guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced‐stage classic Hodgkin lymphoma (JCOG1305)

Shigeru Kusumoto iD, Wataru Munakata iD, Ryunosuke Machida, Takashi Terauchi, Hiroaki Onaya, Masahiko Oguchi, Shinsuke Iida iD, Kisato Nosaka iD, Yasuhiro Suzuki, Yasuhiko Harada, Kana Miyazaki iD, Masaki Maruta und 13 weitere

Cancer Science · 2024

DOI: 10.1111/cas.16281 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Shigeru Kusumoto und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan. Hauptthemen laut MEDLINE: Hodgkin Disease, Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Dacarbazine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development, National Cancer Center Research and Development Funds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This single‐arm confirmatory study (JCOG1305) aimed to evaluate the utility of interim positron emission tomography (iPET)‐guided therapy for newly diagnosed advanced‐stage classic Hodgkin lymphoma (cHL). Patients aged 16–60 years with cHL received two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and then underwent an iPET scan (PET2), which was centrally reviewed using a five‐point Deauville scale. PET2‐negative patients continued an additional four cycles of ABVD, whereas PET2‐positive patients switched to six cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP). The co‐primary endpoints were 2‐year progression‐free survival (PFS) among all eligible and PET2‐positive patients. Ninety‐three patients were enrolled between January 2016 and December 2019. One patient was ineligible because of a diagnostic error. The median age of the 92 eligible patients was 35 (interquartile range, 28–48) years. Forty (43%) patients had stage III disease, and 43 (47%) had stage IV disease. The remaining nine (10%) patients had stage IIB disease with risk factors. Nineteen PET2‐positive (21%) patients received eBEACOPP, 18 completed six cycles of eBEACOPP, 73 PET2‐negative (79%) patients continued ABVD, and 70 completed an additional four cycles of ABVD. With a median follow‐up period of 41.1 months, the 2‐year PFS of 92 eligible patients and 19 PET2‐positive patients were 84.8% (80% confidence interval [CI], 79.2–88.9) and 84.2% (80% CI, 69.7–92.1), respectively. Both primary endpoints were met at the prespecified threshold. This study demonstrates that iPET‐guided therapy is a useful treatment option for younger patients with newly diagnosed advanced‐stage cHL. Registration number: jRCTs031180218.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseAntineoplastic Combined Chemotherapy ProtocolsBleomycinDacarbazineDoxorubicinProcarbazineVincristineVinblastineEtoposidePrednisoneCyclophosphamidePositron-Emission TomographyNeoplasm StagingHumansAdultMiddle AgedFemaleMaleYoung AdultAdolescentProgression-Free Survival

Stichwörter der Autor:innen

ABVDadvanced‐stagecHLescalated BEACOPPinterim PET‐guided

Substanzen

BleomycinDacarbazineDoxorubicinProcarbazineVincristineVinblastineEtoposidePrednisoneCyclophosphamide

Autor:innen und Institutionen

  • Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
  • JCOG Data Center, National Cancer Center Hospital, Tokyo, Japan.
  • Japanese Foundation for Cancer Research Department of Nuclear Medicine, Cancer Institute Hospital, Tokyo, Japan.
  • Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Japan.

ORCID-Profile: Shigeru Kusumoto, Wataru Munakata, Shinsuke Iida, Kisato Nosaka, Kana Miyazaki, Ken Ohmachi, Shinya Rai, Suguru Fukuhara, Mai Takeuchi, Ukihide Tateishi, Dai Maruyama

Förderung

  • Japan Agency for Medical Research and Development
  • National Cancer Center Research and Development Funds

Zitieren

APA

Kusumoto, S., Munakata, W., Machida, R., Terauchi, T., Onaya, H., Oguchi, M., Iida, S., Nosaka, K., Suzuki, Y., Harada, Y., Miyazaki, K., Maruta, M., Fukuhara, N., Toubai, T., Kubota, N., Ohmachi, K., Saito, T., Rai, S., Mizuno, I., …, & Nagai, H. (2024). Interim PET‐guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced‐stage classic Hodgkin lymphoma (JCOG1305). Cancer Science. https://doi.org/10.1111/cas.16281

Vancouver

Kusumoto S, Munakata W, Machida R, Terauchi T, Onaya H, Oguchi M, et al. Interim PET‐guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced‐stage classic Hodgkin lymphoma (JCOG1305). Cancer Science. 2024. doi:10.1111/cas.16281

BibTeX
@article{Kusumoto2024,
  author = {Kusumoto, Shigeru and Munakata, Wataru and Machida, Ryunosuke and Terauchi, Takashi and Onaya, Hiroaki and Oguchi, Masahiko and Iida, Shinsuke and Nosaka, Kisato and Suzuki, Yasuhiro and Harada, Yasuhiko and Miyazaki, Kana and Maruta, Masaki and Fukuhara, Noriko and Toubai, Tomomi and Kubota, Nobuko and Ohmachi, Ken and Saito, Toko and Rai, Shinya and Mizuno, Ishikazu and Fukuhara, Suguru and Takeuchi, Mai and Tateishi, Ukihide and Maruyama, Dai and Tsukasaki, Kunihiro and Nagai, Hirokazu},
  title = {Interim PET‐guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced‐stage classic Hodgkin lymphoma (JCOG1305)},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.16281}
}
Kostenlos starten →